Wouter Joustra

CIK: 0001897813

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ENGN

enGene Therapeutics Inc.

Director

VOR

Vor Biopharma Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

ENGN
enGene Therapeutics Inc.
Jun 16, 2026
Award(A)
Stock Option (Right to Buy)
Direct
31K shares-
VOR
Vor Biopharma Inc.
Jun 11, 2026
Award(A)
Stock option (right to buy)
Direct
57.2K shares-
VOR
Vor Biopharma Inc.
Dec 18, 2025
Award(A)
Stock Option (Right to Buy)
Direct
3K shares-
ENGN
enGene Holdings Inc.
Jun 16, 2025
Award(A)
Stock Option (Right to Buy)
Direct
22.5K shares-

		Type	Shares	Price		Ownership
Jun 16, 2026	ENGN enGene Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	31,000	-	-	Direct
Jun 11, 2026	VOR Vor Biopharma Inc.	Award(A) Stock option (right to buy)	57,162	-	-	Direct
Dec 18, 2025	VOR Vor Biopharma Inc.	Award(A) Stock Option (Right to Buy)	3,000	-	-	Direct
Jun 16, 2025	ENGN enGene Holdings Inc.	Award(A) Stock Option (Right to Buy)	22,500	-	-	Direct

1-4 of 4 transactions

About Joustra Wouter

Joustra Wouter (SEC CIK 0001897813) files insider reports with the SEC as Director of enGene Therapeutics Inc. (ENGN) and Director of Vor Biopharma Inc. (VOR).

Signal8 holds 5 ownership filings by Joustra Wouter (1 Form 3, 4 Form 4), filed between Jun 16, 2025 and Jun 17, 2026. Those filings report 4 transactions, from Jun 16, 2025 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Joustra Wouter's filings is in BOSTON, MA.

Recent filings by Joustra Wouter

Jun 16, 2026: Grant or award of ENGN derivative securities (Form 4, code A).
Jun 11, 2026: Grant or award of VOR derivative securities (Form 4, code A).
Dec 18, 2025: Grant or award of VOR derivative securities (Form 4, code A).
Jun 16, 2025: Grant or award of ENGN derivative securities (Form 4, code A).

Other insiders filing for enGene Therapeutics Inc. (ENGN)

Grossman William, Interim Chief Medical Officer
Chinoporos Constantine, Interim Chief Business Officer
Richton Kathleen P., SVP, Finance and Treasurer
Astley-Sparke Philip, Director
BRUNK GERALD A, Director
Glickman Richard M, Director

How to read Form 4 transaction codes